{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:02Z","timestamp":1790701502728,"version":"4.1.0"},"reference-count":149,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Science and Technology Project","award":["2025KY1547"],"award-info":[{"award-number":["2025KY1547"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Bruton\u2019s tyrosine kinase inhibitors (BTKIs) have become the first-line treatment for B-cell malignancies such as chronic lymphocytic leukemia, significantly improving patient outcomes. However, hypertension is a common and critical cardiovascular adverse effect of BTKIs, with incidence rates ranging from 23% to 75%. For some patients, traditional antihypertensive therapy is ineffective, creating significant risks to cardiovascular safety and the sustainability of the treatment plan. Current reviews have primarily addressed general BTKI cardiotoxicity or isolated signaling pathways, failing to systematically analyze how the proprotein convertase subtilisin\/kexin type 9 (PCSK9)\/Notch3 pathway coordinates hypertension. Furthermore, current reviews lack comprehensive integration of individual susceptibility and mechanism-targeted strategies. Thus, this review systematically evaluates the epidemiological characteristics, molecular mechanisms, individual risk-modifying factors, and management strategies of BTKI-related hypertension by searching the PubMed, Embase, and Web of Science databases (up to 2025). Key findings suggest that BTKIs induce endothelial dysfunction and increase peripheral mechanisms through multiple mechanisms. These agents promote vascular inflammation, remodeling, and altered lipid metabolism by upregulating PCSK9, abnormally activating Notch3 signaling, increasing renin\u2013angiotensin\u2013aldosterone system activity, and driving nicotinamide adenine dinucleotide phosphate (NADPH) oxidase\u2013reactive oxygen species-mediated oxidative stress. Additionally, off-target inhibition of TEC\/interleukin 2-inducible T-cell kinase contributes to these adverse vascular effects. Disease risk is further modified by Notch3\/PCSK9 gene polymorphisms and clinical features such as existing cardiovascular disease and advanced age. Clinical management primarily relies on traditional antihypertensive drugs such as angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers, as well as calcium channel blockers. In contrast, novel intervention strategies such as PCSK9 inhibitors and curcumin show potential advantages. To our knowledge, this review systematically elaborates the core role of the PCSK9\/Notch3 signaling pathway in BTKI-related hypertension, integrating the \u201cmechanism \u2013 susceptibility \u2013 intervention\u201d three-dimensional network, providing a theoretical basis for precise risk stratification and individualized treatment, and promoting the dual optimization of cardiovascular protection and anti-tumor therapy.<\/jats:p>","DOI":"10.31083\/fbl47763","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:51Z","timestamp":1790698911000},"source":"Crossref","is-referenced-by-count":0,"title":["Mechanism and Individualized Management of Hypertension Associated With Bruton Tyrosine Kinase Inhibitors: The PCSK9\/Notch3 Signaling Pathway"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0601-0054","authenticated-orcid":true,"given":"Bingtao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7465-8442","authenticated-orcid":true,"given":"Junling","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3939-3941","authenticated-orcid":true,"given":"Kan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0417-6268","authenticated-orcid":true,"given":"Xueqi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2810-1102","authenticated-orcid":true,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9600-9956","authenticated-orcid":true,"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First Affiliated Hospital of Huzhou Normal University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hallek M. Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. American Journal of Hematology. 2025; 100: 450\u2013480.","DOI":"10.1002\/ajh.27546"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, et al. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 2018; 18: 648\u2013657.e15.","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019; 134: 1919\u20131928.","DOI":"10.1182\/blood.2019000840"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zegeye MM, Lindkvist M, F\u00e4lker K, Kumawat AK, Paramel G, Greneg\u00e5rd M, et al. Activation of the JAK\/STAT3 and PI3K\/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Communication and Signaling : CCS. 2018; 16: 55.","DOI":"10.1186\/s12964-018-0268-4"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wang S, Clapper E, Tonissen KF, Di Trapani G. Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma. Antioxidants (Basel, Switzerland). 2023; 12: 529.","DOI":"10.3390\/antiox12020529"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK, et al. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nature Immunology. 2012; 13: 369\u2013378.","DOI":"10.1038\/ni.2234"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vetrie D, Vorechovsk\u00fd I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993; 361: 226\u2013233.","DOI":"10.1038\/361226a0"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (New York, N.Y.). 1995; 267: 886\u2013891.","DOI":"10.1126\/science.7531365"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Uckun FM, Waddick KG, Mahajan S, Jun X, Takata M, Bolen J, et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science (New York, N.Y.). 1996; 273: 1096\u20131100.","DOI":"10.1126\/science.273.5278.1096"},{"key":"ref10","unstructured":"Technology Networks. Pharmacyclics initiates Phase 1 clinical trial of oral Btk inhibitor for refractory B-cell Non-Hodgkin's lymphoma. Available at: https:\/\/www.technologynetworks.com\/drug-discovery\/news\/pharmacyclics-initiates-phase-1-clinical-trial-of-oral-btk-inhibitor-for-refractory-bcell-nonhodgkins-lymphoma-205226 (Accessed: 15 April 2009)."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2013; 31: 88\u201394.","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. The Lancet. Oncology. 2014; 15: 48\u201358.","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014; 124: 3829\u20133830.","DOI":"10.1182\/blood-2014-10-604272"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Profit\u00f3s-Pelej\u00e0 N, Santos JC, Mar\u00edn-Niebla A, Rou\u00e9 G, Ribeiro ML. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. Cancers. 2022; 14: 860.","DOI":"10.3390\/cancers14040860"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Koehrer S, Burger JA. Chronic Lymphocytic Leukemia: Disease Biology. Acta Haematologica. 2024; 147: 8\u201321.","DOI":"10.1159\/000533610"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Law DA, Chan VW, Datta SK, DeFranco AL. B-cell antigen receptor motifs have redundant signalling capabilities and bind the tyrosine kinases PTK72, Lyn and Fyn. Current Biology : CB. 1993; 3: 645\u2013657.","DOI":"10.1016\/0960-9822(93)90062-s"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hitomi T, Yanagi S, Inatome R, Yamamura H. Cross-linking of the B cell receptor induces activation of phospholipase D through Syk, Btk and phospholipase C-gamma2. FEBS Letters. 1999; 445: 371\u2013374.","DOI":"10.1016\/s0014-5793(99)00153-2"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T, et al. BLNK mediates Syk-dependent Btk activation. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 2582\u20132586.","DOI":"10.1073\/pnas.051626198"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Inabe K, Miyawaki T, Longnecker R, Matsukura H, Tsukada S, Kurosaki T. Bruton's tyrosine kinase regulates B cell antigen receptor-mediated JNK1 response through Rac1 and phospholipase C-gamma2 activation. FEBS Letters. 2002; 514: 260\u2013262.","DOI":"10.1016\/s0014-5793(02)02375-x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Tomlinson MG, Woods DB, McMahon M, Wahl MI, Witte ON, Kurosaki T, et al. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. BMC Immunology. 2001; 2: 4.","DOI":"10.1186\/1471-2172-2-4"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Feng B, Cheng S, Hsia CY, King LB, Monroe JG, Liou HC. NF-kappaB inducible genes BCL-X and cyclin E promote immature B-cell proliferation and survival. Cellular Immunology. 2004; 232: 9\u201320.","DOI":"10.1016\/j.cellimm.2005.01.006"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Piatelli MJ, Doughty C, Chiles TC. Requirement for a hsp90 chaperone-dependent MEK1\/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. The Journal of Biological Chemistry. 2002; 277: 12144\u201312150.","DOI":"10.1074\/jbc.M200102200"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Kil LP, de Bruijn MJW, van Nimwegen M, Corneth OBJ, van Hamburg JP, Dingjan GM, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012; 119: 3744\u20133756.","DOI":"10.1182\/blood-2011-12-397919"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Shinnakasu R, Inoue T, Kometani K, Moriyama S, Adachi Y, Nakayama M, et al. Regulated selection of germinal-center cells into the memory B cell compartment. Nature Immunology. 2016; 17: 861\u2013869.","DOI":"10.1038\/ni.3460"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91: 231\u2013241.","DOI":"10.1016\/s0092-8674(00)80405-5"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Advances. 2024; 8: 2300\u20132309.","DOI":"10.1182\/bloodadvances.2023012221"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Plante TB, Koh I, Judd SE, Howard G, Howard VJ, Zakai NA, et al. Life's Simple 7 and Incident Hypertension: The REGARDS Study. Journal of the American Heart Association. 2020; 9: e016482.","DOI":"10.1161\/JAHA.120.016482"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: a Cancer Journal for Clinicians. 2016; 66: 309\u2013325.","DOI":"10.3322\/caac.21341"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117: 6287\u20136296.","DOI":"10.1182\/blood-2011-01-328484"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119: 1182\u20131189.","DOI":"10.1182\/blood-2011-10-386417"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"de Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012; 119: 2590\u20132594.","DOI":"10.1182\/blood-2011-11-390989"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018; 103: 874\u2013879.","DOI":"10.3324\/haematol.2017.182907"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023; 142: 687\u2013699.","DOI":"10.1182\/blood.2022018818"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Phillips T, Wang M, Robak T, Gallinson D, Stevens D, Patel K, et al. Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-na\u00efve or relapsed\/refractory mantle cell lymphoma: phase Ib trial. Haematologica. 2025; 110: 715\u2013724.","DOI":"10.3324\/haematol.2023.284896"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022; 139: 3148\u20133158.","DOI":"10.1182\/blood.2021014162"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Brown JR, Eichhorst B, Lamanna N, O'Brien SM, Tam CS, Qiu L, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood. 2024; 144: 2706\u20132717.","DOI":"10.1182\/blood.2024024667"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study. Blood Advances. 2023; 7: 4349\u20134357.","DOI":"10.1182\/bloodadvances.2022009168"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial. Haematologica. 2025; 110: 92\u2013102.","DOI":"10.3324\/haematol.2024.285754"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, et al. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Advances. 2023; 7: 4291\u20134301.","DOI":"10.1182\/bloodadvances.2023009739"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Lee DH, Hawk F, Seok K, Gliksman M, Emole J, Rhea IB, et al. Association between ibrutinib treatment and hypertension. Heart (British Cardiac Society). 2022; 108: 445\u2013450.","DOI":"10.1136\/heartjnl-2021-319110"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Adasme MF, Parisi D, Van Belle K, Salentin S, Haupt VJ, Jennings GS, et al. Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PloS One. 2020; 15: e0233089.","DOI":"10.1371\/journal.pone.0233089"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Huang X, Zhou G, Wu W, Ma G, D'Amore PA, Mukai S, et al. Editing VEGFR2 Blocks VEGF-Induced Activation of Akt and Tube Formation. Investigative Ophthalmology & Visual Science. 2017; 58: 1228\u20131236.","DOI":"10.1167\/iovs.16-20537"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Zhang Y, Khoi PN, Cai B, Sah DK, Jung YD. Sulforaphane Regulates eNOS Activation and NO Production via Src-Mediated PI3K\/Akt Signaling in Human Endothelial EA.hy926 Cells. Molecules (Basel, Switzerland). 2022; 27: 5422.","DOI":"10.3390\/molecules27175422"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Yang X, An N, Zhong C, Guan M, Jiang Y, Li X, et al. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation. Redox Biology. 2020; 30: 101432.","DOI":"10.1016\/j.redox.2020.101432"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009; 459: 712\u2013716.","DOI":"10.1038\/nature07969"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (New York, N.Y.). 2008; 319: 1676\u20131679.","DOI":"10.1126\/science.1153629"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Kim DH, Meza CA, Clarke H, Kim JS, Hickner RC. Vitamin D and Endothelial Function. Nutrients. 2020; 12: 575.","DOI":"10.3390\/nu12020575"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Ye P, Jiang XM, Qian WC, Zhang J. Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression. Cardiovascular Drugs and Therapy. 2024; 38: 1223\u20131234.","DOI":"10.1007\/s10557-023-07458-9"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Hosseini-Alghaderi S, Baron M. Notch3 in Development, Health and Disease. Biomolecules. 2020; 10: 485.","DOI":"10.3390\/biom10030485"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009; 203: 1\u20137.","DOI":"10.1016\/j.atherosclerosis.2008.06.010"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 928\u2013933.","DOI":"10.1073\/pnas.0335507100"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Fagerberg L, Hallstr\u00f6m BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular & Cellular Proteomics : MCP. 2014; 13: 397\u2013406.","DOI":"10.1074\/mcp.M113.035600"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017; 38: 2459\u20132472.","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Urban D, P\u00f6ss J, B\u00f6hm M, Laufs U. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Journal of the American College of Cardiology. 2013; 62: 1401\u20131408.","DOI":"10.1016\/j.jacc.2013.07.056"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Ding Z, Pothineni NVK, Goel A, L\u00fcscher TF, Mehta JL. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovascular Research. 2020; 116: 908\u2013915.","DOI":"10.1093\/cvr\/cvz313"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Aboukhater D, Morad B, Nasrallah N, Nasser SA, Sahebkar A, Kobeissy F, et al. Inflammation and hypertension: Underlying mechanisms and emerging understandings. Journal of Cellular Physiology. 2023; 238: 1148\u20131159.","DOI":"10.1002\/jcp.31019"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Berger JM, Vaillant N, Le May C, Calderon C, Br\u00e9geon J, Prieur X, et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis. 2015; 239: 252\u2013259.","DOI":"10.1016\/j.atherosclerosis.2015.01.012"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, et al. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leukemia & Lymphoma. 2018; 59: 2686\u20132691.","DOI":"10.1080\/10428194.2018.1439167"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Sun J, Dong M, Xiang X, Zhang S, Wen D. Notch signaling and targeted therapy in non-small cell lung cancer. Cancer Letters. 2024; 585: 216647.","DOI":"10.1016\/j.canlet.2024.216647"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Kovall RA, Gebelein B, Sprinzak D, Kopan R. The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. Developmental Cell. 2017; 41: 228\u2013241.","DOI":"10.1016\/j.devcel.2017.04.001"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Wang W, Li G, Ma J, Fan X, Lu J, Sun Q, et al. Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage. Frontiers in Pharmacology. 2024; 15: 1346905.","DOI":"10.3389\/fphar.2024.1346905"},{"key":"ref62","unstructured":"Tang SC, Jeng JS, Lee MJ, Yip PK. Notch signaling and CADASIL. Acta Neurologica Taiwanica. 2009; 18: 81\u201390."},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development (Cambridge, England). 2011; 138: 3593\u20133612.","DOI":"10.1242\/dev.063610"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Liu H, Kennard S, Lilly B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circulation Research. 2009; 104: 466\u2013475.","DOI":"10.1161\/CIRCRESAHA.108.184846"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes & Development. 2004; 18: 2730\u20132735.","DOI":"10.1101\/gad.308904"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, et al. Kr\u00fcppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respiratory Research. 2011; 12: 128.","DOI":"10.1186\/1465-9921-12-128"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Li X, He Y, Xu Y, Huang X, Liu J, Xie M, et al. KLF5 mediates vascular remodeling via HIF-1\u03b1 in hypoxic pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2016; 310: L299\u2013310.","DOI":"10.1152\/ajplung.00189.2015"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2011; 25: 1922\u20131933.","DOI":"10.1096\/fj.10-175018"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology. 2013; 48: 568\u2013577.","DOI":"10.1165\/rcmb.2012-0429OC"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Chen X, Zhou W, Hu Q, Huang L. Exploration of the Notch3-HES5 signal pathway in monocrotaline-induced pulmonary hypertension using rat model. Congenital Heart Disease. 2019; 14: 396\u2013402.","DOI":"10.1111\/chd.12733"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Gao JJ, Wu FY, Liu YJ, Li L, Lin YJ, Kang YT, et al. Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing. Science China. Life Sciences. 2024; 67: 2635\u20132649.","DOI":"10.1007\/s11427-023-2688-8"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Xiang Q, Liu WF, Zeng JL, Deng YM, Peng J, Liu HT, et al. Effect of PCSK9 on Vascular Smooth Muscle Cell Functions: A New Player in Atherosclerosis. Current Medicinal Chemistry. 2021; 28: 7446\u20137460.","DOI":"10.2174\/0929867328666210531150302"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Ferri N, Marchian\u00f2 S, Tibolla G, Baetta R, Dhyani A, Ruscica M, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016; 253: 214\u2013224.","DOI":"10.1016\/j.atherosclerosis.2016.07.910"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. Journal of Nephrology. 2011; 24: 23\u201334.","DOI":"10.5301\/jn.2010.4729"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Tomiyama H, Shiina K, Vlachopoulos C, Iwasaki Y, Matsumoto C, Kimura K, et al. Involvement of Arterial Stiffness and Inflammation in Hyperuricemia-Related Development of Hypertension. Hypertension (Dallas, Tex. : 1979). 2018; 72: 739\u2013745.","DOI":"10.1161\/HYPERTENSIONAHA.118.11390"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022; 107: 1335\u20131346.","DOI":"10.3324\/haematol.2021.278901"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology. 2019; 74: 1667\u20131678.","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. 2013; 369: 32\u201342.","DOI":"10.1056\/NEJMoa1215637"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Bergl\u00f6f A, Hamasy A, Meinke S, Palma M, Krstic A, M\u00e5nsson R, et al. Targets for Ibrutinib Beyond B Cell Malignancies. Scandinavian Journal of Immunology. 2015; 82: 208\u2013217.","DOI":"10.1111\/sji.12333"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 13075\u201313080.","DOI":"10.1073\/pnas.1004594107"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Frontiers in Cell and Developmental Biology. 2021; 9: 630942.","DOI":"10.3389\/fcell.2021.630942"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology. American Society of Hematology. Education Program. 2020; 2020: 336\u2013345.","DOI":"10.1182\/hematology.2020000118"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Ahn IE. Cardiovascular adverse events of ibrutinib. Blood. 2019; 134: 1881\u20131882.","DOI":"10.1182\/blood.2019002805"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Yin Z, Zou Y, Wang D, Huang X, Xiong S, Cao L, et al. Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discovery. 2022; 8: 119.","DOI":"10.1038\/s41420-022-00927-4"},{"key":"ref85","unstructured":"Kl\u00fcppel M, Donoviel DB, Brunkow ME, Motro B, Bernstein A. Embryonic and adult expression patterns of the Tec tyrosine kinase gene suggest a role in megakaryocytopoiesis, blood vessel development, and melanogenesis. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research. 1997; 8: 1249\u20131256."},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, et al. Etk\/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. The Journal of Biological Chemistry. 2003; 278: 51267\u201351276.","DOI":"10.1074\/jbc.M310678200"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Rajantie I, Ekman N, Iljin K, Arighi E, Gunji Y, Kaukonen J, et al. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Molecular and Cellular Biology. 2001; 21: 4647\u20134655.","DOI":"10.1128\/MCB.21.14.4647-4655.2001"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"He Y, Luo Y, Tang S, Rajantie I, Salven P, Heil M, et al. Critical function of Bmx\/Etk in ischemia-mediated arteriogenesis and angiogenesis. The Journal of Clinical Investigation. 2006; 116: 2344\u20132355.","DOI":"10.1172\/JCI28123"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Zhao Y, Qian Y, Sun Z, Shen X, Cai Y, Li L, et al. Role of PI3K in the Progression and Regression of Atherosclerosis. Frontiers in Pharmacology. 2021; 12: 632378.","DOI":"10.3389\/fphar.2021.632378"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Sagan D, Eckardt-Schupp F, Eichholtz-Wirth H. Reduced expression of SRC family kinases decreases PI3K activity in NBS1-\/- lymphoblasts. Biochemical and Biophysical Research Communications. 2008; 377: 181\u2013186.","DOI":"10.1016\/j.bbrc.2008.09.098"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. The American Journal of Pathology. 2009; 175: 998\u20131009.","DOI":"10.2353\/ajpath.2009.090126"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Ezeani M, Prabhu S. Pathophysiology and therapeutic relevance of PI3K(p110\u03b1) protein in atrial fibrillation: A non-interventional molecular therapy strategy. Pharmacological Research. 2021; 165: 105415.","DOI":"10.1016\/j.phrs.2020.105415"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Gao HL, Yu XJ, Feng YQ, Yang Y, Hu HB, Zhao YY, et al. Luteolin Attenuates Hypertension via Inhibiting NF-\u03baB-Mediated Inflammation and PI3K\/Akt Signaling Pathway in the Hypothalamic Paraventricular Nucleus. Nutrients. 2023; 15: 502.","DOI":"10.3390\/nu15030502"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Veerasingham SJ, Yamazato M, Berecek KH, Wyss JM, Raizada MK. Increased PI3-kinase in presympathetic brain areas of the spontaneously hypertensive rat. Circulation Research. 2005; 96: 277\u2013279.","DOI":"10.1161\/01.RES.0000156275.06641.b2"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Anannya O, Huang W, August A. The kinase ITK controls a Ca2+-mediated switch that balances TH17 and Treg cell differentiation. Science Signaling. 2024; 17: eadh2381.","DOI":"10.1126\/scisignal.adh2381"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Lechner KS, Neurath MF, Weigmann B. Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. Journal of Molecular Medicine (Berlin, Germany). 2020; 98: 1385\u20131395.","DOI":"10.1007\/s00109-020-01958-z"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Huang W, Morales JL, Gazivoda VP, August A. Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide. The Journal of Allergy and Clinical Immunology. 2016; 137: 1197\u20131205.","DOI":"10.1016\/j.jaci.2015.08.056"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132: 344\u2013362.","DOI":"10.1016\/j.cell.2008.01.020"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Kracht M, M\u00fcller-Ladner U, Schmitz ML. Mutual regulation of metabolic processes and proinflammatory NF-\u03baB signaling. The Journal of Allergy and Clinical Immunology. 2020; 146: 694\u2013705.","DOI":"10.1016\/j.jaci.2020.07.027"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Capece D, Verzella D, Flati I, Arboretto P, Cornice J, Franzoso G. NF-\u03baB: blending metabolism, immunity, and inflammation. Trends in Immunology. 2022; 43: 757\u2013775.","DOI":"10.1016\/j.it.2022.07.004"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Cui Y, Benamar M, Schmitz-Abe K, Poondi-Krishnan V, Chen Q, Jugder BE, et al. A Stk4-Foxp3-NF-\u03baB p65 transcriptional complex promotes Treg cell activation and homeostasis. Science Immunology. 2022; 7: eabl8357.","DOI":"10.1126\/sciimmunol.abl8357"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Research. 2001; 3: 200\u2013206.","DOI":"10.1186\/ar300"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Ilchovska DD, Barrow DM. An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions. Autoimmunity Reviews. 2021; 20: 102741.","DOI":"10.1016\/j.autrev.2020.102741"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Xu J, Lin J, Gan H, He Q, Wang W, Liu Y. Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases. Frontiers in Pharmacology. 2025; 16: 1585061.","DOI":"10.3389\/fphar.2025.1585061"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Marcelli M, Bi C, Funder JW, McPhaul MJ. Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism. Hypertension (Dallas, Tex. : 1979). 2024; 81: 2072\u20132081.","DOI":"10.1161\/HYPERTENSIONAHA.124.22884"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Zhang J, Rudemiller NP, Patel MB, Karlovich NS, Wu M, McDonough AA, et al. Interleukin-1 Receptor Activation Potentiates Salt Reabsorption in Angiotensin II-Induced Hypertension via the NKCC2 Co-transporter in the Nephron. Cell Metabolism. 2016; 23: 360\u2013368.","DOI":"10.1016\/j.cmet.2015.11.013"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nature Reviews. Immunology. 2019; 19: 517\u2013532.","DOI":"10.1038\/s41577-019-0160-5"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, et al. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological Reviews. 2018; 98: 1627\u20131738.","DOI":"10.1152\/physrev.00038.2017"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Zhang D, Liu Y, Zaidi SA, Xu L, Zhan Y, Chen A, et al. Structural insights into angiotensin receptor signaling modulation by balanced and biased agonists. The EMBO Journal. 2023; 42: e112940.","DOI":"10.15252\/embj.2022112940"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 14483\u201314488.","DOI":"10.1073\/pnas.94.26.14483"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews. 2007; 87: 245\u2013313.","DOI":"10.1152\/physrev.00044.2005"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Violi F, Oliva A, Cangemi R, Ceccarelli G, Pignatelli P, Carnevale R, et al. Nox2 activation in Covid-19. Redox Biology. 2020; 36: 101655.","DOI":"10.1016\/j.redox.2020.101655"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Rothfork JM, Timmins GS, Harris MN, Chen X, Lusis AJ, Otto M, et al. Inactivation of a bacterial virulence pheromone by phagocyte-derived oxidants: new role for the NADPH oxidase in host defense. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 13867\u201313872.","DOI":"10.1073\/pnas.0402996101"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Vermot A, Petit-H\u00e4rtlein I, Smith SME, Fieschi F. NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology. Antioxidants (Basel, Switzerland). 2021; 10: 890.","DOI":"10.3390\/antiox10060890"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxidants & Redox Signaling. 2014; 20: 1126\u20131167.","DOI":"10.1089\/ars.2012.5149"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. International Journal of Environmental Research and Public Health. 2013; 10: 3886\u20133907.","DOI":"10.3390\/ijerph10093886"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Davies MJ. The oxidative environment and protein damage. Biochimica et Biophysica Acta. 2005; 1703: 93\u2013109.","DOI":"10.1016\/j.bbapap.2004.08.007"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Hazen SL, Hsu FF, Gaut JP, Crowley JR, Heinecke JW. Modification of proteins and lipids by myeloperoxidase. Methods in Enzymology. 1999; 300: 88\u2013105.","DOI":"10.1016\/s0076-6879(99)00117-2"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Zhang GX, Lu XM, Kimura S, Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovascular Research. 2007; 76: 204\u2013212.","DOI":"10.1016\/j.cardiores.2007.07.014"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Wenzel S, Taimor G, Piper HM, Schl\u00fcter KD. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2001; 15: 2291\u20132293.","DOI":"10.1096\/fj.00-0827fje"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Qin F, Patel R, Yan C, Liu W. NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radical Biology & Medicine. 2006; 40: 236\u2013246.","DOI":"10.1016\/j.freeradbiomed.2005.08.010"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Nox4 mediates angiotensin II-induced activation of Akt\/protein kinase B in mesangial cells. American Journal of Physiology. Renal Physiology. 2003; 285: F219\u2013F229.","DOI":"10.1152\/ajprenal.00414.2002"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Davis-Knowlton J, Turner JE, Turner A, Damian-Loring S, Hagler N, Henderson T, et al. Characterization of smooth muscle cells from human atherosclerotic lesions and their responses to Notch signaling. Laboratory Investigation; a Journal of Technical Methods and Pathology. 2019; 99: 290\u2013304.","DOI":"10.1038\/s41374-018-0072-1"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Chen CH, Cheng YW, Zhang R, Tezenas Du Montcel S, Guey S, Herv\u00e9 D, et al. Intracerebral Hemorrhage in Patients With CADASIL: Additive Impact of the NOTCH3 R544C Variant and Hypertension? Stroke. 2025; 56: 2159\u20132166.","DOI":"10.1161\/STROKEAHA.124.050484"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. Journal of the American College of Cardiology. 2010; 55: 2833\u20132842.","DOI":"10.1016\/j.jacc.2010.02.044"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Ero\u011flu Z, Tetik Vardarl\u0131 A, D\u00fczg\u00fcn Z, G\u00fcnd\u00fcz C, Bozok \u00c7etinta\u015f V, Kay\u0131k\u00e7\u0131o\u011flu M. Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. Anatolian Journal of Cardiology. 2018; 19: 334\u2013340.","DOI":"10.14744\/AnatolJCardiol.2018.86648"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Gamboa A, Shibao C, Diedrich A, Choi L, Pohar B, Jordan J, et al. Contribution of endothelial nitric oxide to blood pressure in humans. Hypertension (Dallas, Tex. : 1979). 2007; 49: 170\u2013177.","DOI":"10.1161\/01.HYP.0000252425.06216.26"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxidants & Redox Signaling. 2009; 11: 1913\u20131928.","DOI":"10.1089\/ars.2009.2453"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Thomas GD, Zhang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. JAMA. 2001; 285: 2055\u20132057.","DOI":"10.1001\/jama.285.16.2055"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995; 377: 239\u2013242.","DOI":"10.1038\/377239a0"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"J\u00edra M, Z\u00e1vodn\u00e1 E, Honz\u00edkov\u00e1 N, Nov\u00e1kov\u00e1 Z, Va\u0161k\u016f A, Izakovi\u010dov\u00e1 Holl\u00e1 L, et al. Association of eNOS gene polymorphisms T-786C and G894T with blood pressure variability in man. Physiological Research. 2011; 60: 193\u2013197.","DOI":"10.33549\/physiolres.931887"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Neto ABL, Farias MCO, Vasconcelos NBR, Xavier AF Jr, Assun\u00e7\u00e3o ML, Ferreira HS. Prevalence of endothelial nitric oxide synthase (ENOS) gene G894T polymorphism and its association with hypertension: a population-based study with Brazilian women. Archives of Medical Sciences. Atherosclerotic Diseases. 2019; 4: e63\u2013e73.","DOI":"10.5114\/amsad.2019.84539"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024; 45: 3912\u20134018.","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine. 2020; 382: 1507\u20131519.","DOI":"10.1056\/NEJMoa1912387"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clinical Pharmacokinetics. 2018; 57: 769\u2013779.","DOI":"10.1007\/s40262-017-0620-7"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Seidah NG, Prat A. The Multifaceted Biology of PCSK9. Endocrine Reviews. 2022; 43: 558\u2013582.","DOI":"10.1210\/endrev\/bnab035"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of Clinical Lipidology. 2023; 17: 392\u2013400.","DOI":"10.1016\/j.jacl.2023.04.010"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Mohan M, Hussain MA, Khan FA, Anindya R. Symmetrical and un-symmetrical curcumin analogues as selective COX-1 and COX-2 inhibitor. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 2021; 160: 105743.","DOI":"10.1016\/j.ejps.2021.105743"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Zhang J, Zheng Y, Luo Y, Du Y, Zhang X, Fu J. Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2\/ TLR4\/ NF-\u03baB pathways in BV2 cells. Molecular Immunology. 2019; 116: 29\u201337.","DOI":"10.1016\/j.molimm.2019.09.020"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Rahban M, Habibi-Rezaei M, Mazaheri M, Saso L, Moosavi-Movahedi AA. Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications. Antioxidants (Basel, Switzerland). 2020; 9: 1228.","DOI":"10.3390\/antiox9121228"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Liu J, Huang C, Liu J, Meng C, Gu Q, Du X, et al. Nrf2 and its dependent autophagy activation cooperatively counteract ferroptosis to alleviate acute liver injury. Pharmacological Research. 2023; 187: 106563.","DOI":"10.1016\/j.phrs.2022.106563"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Saeedi F, Farkhondeh T, Roshanravan B, Amirabadizadeh A, Ashrafizadeh M, Samarghandian S. Curcumin and blood lipid levels: an updated systematic review and meta-analysis of randomised clinical trials. Archives of Physiology and Biochemistry. 2022; 128: 1493\u20131502.","DOI":"10.1080\/13813455.2020.1779309"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Molecular Nutrition & Food Research. 2014; 58: 2133\u20132145.","DOI":"10.1002\/mnfr.201400366"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. The AAPS Journal. 2013; 15: 195\u2013218.","DOI":"10.1208\/s12248-012-9432-8"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Kouhpeikar H, Butler AE, Bamian F, Barreto GE, Majeed M, Sahebkar A. Curcumin as a therapeutic agent in leukemia. Journal of Cellular Physiology. 2019; 234: 12404\u201312414.","DOI":"10.1002\/jcp.28072"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, et al. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry. 2018; 57: 3564\u20133575.","DOI":"10.1021\/acs.biochem.8b00391"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology. 2021; 22: 790\u2013800.","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Liu D, Mao W, Hu B, Li X, Zhao Q, Zhang L, et al. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS). Frontiers in Pharmacology. 2024; 15: 1405023.","DOI":"10.3389\/fphar.2024.1405023"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Karthikeyan B, Sunder SS, Puzanov I, Olejniczak SH, Pokharel S, Sharma UC. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers. Communications Medicine. 2024; 4: 116.","DOI":"10.1038\/s43856-024-00540-9"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL47763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:22:53Z","timestamp":1790698973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL47763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":149,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02046-0"],"URL":"https:\/\/doi.org\/10.31083\/fbl47763","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"47763"}}